{"nctId":"NCT02873208","briefTitle":"A Phase 3, Long-term Safety and Tolerability Study of ALKS 3831 in Adults With Schizophrenia","startDateStruct":{"date":"2016-08-07","type":"ACTUAL"},"conditions":["Schizophrenia"],"count":266,"armGroups":[{"label":"ALKS 3831","type":"EXPERIMENTAL","interventionNames":["Drug: ALKS 3831"]}],"interventions":[{"name":"ALKS 3831","otherNames":[]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n* Agrees to use an acceptable method of contraception for the duration of the study\n* Subject has completed the 24-week treatment period in the antecedent study, ALK3831-A303, within 7 days\n* Additional criteria may apply\n\nExclusion Criteria:\n\n* Subject is currently taking medications that are contraindicated with olanzapine use or exhibit drug-interaction potential with olanzapine\n* Subject has a positive test for drugs of abuse at study entry\n* Subject is pregnant, planning to become pregnant, or breastfeeding during the study\n* Additional criteria may apply","healthyVolunteers":false,"sex":"ALL","minimumAge":"18 Years","maximumAge":"55 Years","stdAges":["ADULT"]},"locations":{"multicenter":true},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Number of Subjects With Adverse Events","description":"Overall summary of treatment emergent adverse events during the treatment period","paramType":"COUNT_OF_PARTICIPANTS","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"161","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"93","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"61","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"7","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"82","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"79","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"15","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"5","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"4","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"1","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":5,"n":265},"commonTop":["Weight decreased","Extra dose administered","Headache","Weight increased","Upper respiratory tract infection"]}}}